Search

everythinglearnresearchcommunity

for

Search:↓

A 24-year-old male has been struggling with hair loss since 2020, trying treatments like minoxidil, finasteride, dutasteride, PRP, vitamins, proteins, and exosomes, but hasn't seen significant improvement. He is considering a hair transplant due to the lack of results from these treatments.

The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

A user shared their positive experience with PRP and stem cell treatment for hair loss, noting it nearly stopped their hair loss after previous use of finasteride and minoxidil. Another user mentioned PRP helped maintain their hair, though its effectiveness decreased over time, and they experienced side effects from dutasteride.

The conversation is about someone using finasteride and minoxidil along with microneedling as a treatment for hair loss, and there's a mention of scalp tattooing as an alternative or additional approach. Some responses mock the approach, while others inquire about the specifics of the treatment and its effectiveness.

The conversation is about using microneedling for hair loss treatment, including questions on disinfection and post-treatment care. The user mentions using oral minoxidil and finasteride, and considering dutasteride.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.

A naturally occurring sugar, 2-deoxy-D-ribose, may promote hair growth by forming new blood vessels. There is skepticism about its effectiveness and concerns about potential side effects, with some users comparing it to existing treatments like Minoxidil and finasteride.

Red flags to watch for when choosing a hair transplant clinic, such as high-pressure sales tactics, unclear surgeon assignments, and unrealistic promises. A user shared a positive experience with Skin Medics UK, highlighting transparency and personalized care.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

The conversation advises against waiting for future hair loss treatments and suggests using proven treatments like Finasteride and Minoxidil. Some users regret not starting treatment earlier, while others discuss the effectiveness and safety of current treatments and the potential of microneedling.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

The user discusses their long struggle with hair loss, considering various treatments like hair transplants, hair systems, and natural methods such as micro-needling, vitamin supplements, and a healthy lifestyle. They express concerns about side effects from drugs like finasteride and ultimately lean towards using a hair system for better appearance and confidence.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

Researchers are working on regenerating hair follicles using stem cells, but a cure for baldness is still years away. Current treatments mentioned include Minoxidil, finasteride, and RU58841.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses hair transplant experiences and decisions, focusing on whether individuals would choose the same doctor again. Treatments mentioned include Minoxidil, finasteride, and RU58841.

A user shared their hair transplant update, having received 4,300 grafts and choosing not to use medications like finasteride or minoxidil due to potential side effects and personal reasons. Many commenters expressed concern that without these medications, the user might experience further hair loss, suggesting that preventative treatments are important for maintaining transplant results.

The conversation is about exploring alternatives for hair loss treatment, specifically ds laboratory revita shampoo and nanoxidil, with the user currently using microneedling. The user is considering these options due to fewer side effects compared to other treatments.

A user shares optimism about combating male pattern baldness using oral and topical minoxidil, highlighting the advancements in treatments available today. Another user agrees, noting that early treatment can yield good results, and mentions the availability of affordable hair transplants.

A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.